Direct cardiac effects of SGLT2 inhibitors
S Chen, R Coronel, MW Hollmann, NC Weber… - Cardiovascular …, 2022 - Springer
Abstract Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …
Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients
L Uthman, A Baartscheer, CA Schumacher… - Frontiers in …, 2018 - frontiersin.org
Sodium glucose cotransporter 2 inhibitors (SGLT2i) are the first antidiabetic compounds that
effectively reduce heart failure hospitalization and cardiovascular death in type 2 diabetics …
effectively reduce heart failure hospitalization and cardiovascular death in type 2 diabetics …
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
A Baartscheer, CA Schumacher, RCI Wüst, JWT Fiolet… - Diabetologia, 2017 - Springer
Abstract Aims/hypothesis Empagliflozin (EMPA), an inhibitor of the renal sodium–glucose
cotransporter (SGLT) 2, reduces the risk of cardiovascular death in patients with type 2 …
cotransporter (SGLT) 2, reduces the risk of cardiovascular death in patients with type 2 …
The control of diastolic calcium in the heart: basic mechanisms and functional implications
Normal cardiac function requires that intracellular Ca2+ concentration be reduced to low
levels in diastole so that the ventricle can relax and refill with blood. Heart failure is often …
levels in diastole so that the ventricle can relax and refill with blood. Heart failure is often …
Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
D Cappetta, A De Angelis, LP Ciuffreda… - Pharmacological …, 2020 - Elsevier
The results of trials with sodium-glucose cotransporter 2 (SGLT2) inhibitors raised the
possibility that this class of drugs provides cardiovascular benefits independently from their …
possibility that this class of drugs provides cardiovascular benefits independently from their …
Reno-and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench
X Chen, CF Hocher, L Shen… - American Journal of …, 2023 - journals.physiology.org
Large placebo-controlled clinical trials have shown that sodium-glucose cotransporter-2
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
M Arow, M Waldman, D Yadin, V Nudelman… - Cardiovascular …, 2020 - Springer
Background Diabetes mellitus type 2 (DM2) is a risk factor for developing heart failure but
there is no specific therapy for diabetic heart disease. Sodium glucose transporter 2 …
there is no specific therapy for diabetic heart disease. Sodium glucose transporter 2 …
RyR2 and calcium release in heart failure
JP Benitah, R Perrier, JJ Mercadier, L Pereira… - Frontiers in …, 2021 - frontiersin.org
Heart Failure (HF) is defined as the inability of the heart to efficiently pump out enough blood
to maintain the body's needs, first at exercise and then also at rest. Alterations in Ca2+ …
to maintain the body's needs, first at exercise and then also at rest. Alterations in Ca2+ …
Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
Diabetes is a global epidemic and a leading cause of death with more than 422 million
patients worldwide out of whom around 392 million alone suffer from type 2 diabetes (T2D) …
patients worldwide out of whom around 392 million alone suffer from type 2 diabetes (T2D) …
[HTML][HTML] SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models
The sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of effective drugs
managing patients, who suffer from type 2 diabetes (T2D): Landmark clinical trials including …
managing patients, who suffer from type 2 diabetes (T2D): Landmark clinical trials including …